OBJECTIVE: No effective medical therapy exists for early abdominal aortic aneurysm (AAA) disease. Lower extremity exercise improves aortic hemodynamics and reduces inflammation, but the safety and efficacy of exercise training in AAA disease is unknown. As an interim analysis of our prospective, randomized, longitudinal trial of exercise for AAA suppression, we investigated whether subjects with early disease could safely achieve target metabolic and hemodynamic goals. METHODS:One hundred eight participants were randomized to exercise training (EX) or usual care (UC). EX subjects participated in a combination of in-house andhome exercise training, with efforts directed toward moderate daily exercise participation. Comparisons were made between EX and UC subjects who completed 1 year of follow-up (n = 26 and 31, respectively, mean age 72 ± 8 years). EX and UC groups were compared for safety, cardiopulmonary exercise test responses, weekly energy expenditure, and biometric indices. RESULTS: No paradoxical increase in AAA growth rate or adverse clinical events occurred as a consequence of exercise training. EX participants expended an average of 2269 ± 1207 kcal/wk and increased exercise capacity (42% increase in treadmill time, 24% increase in estimated metabolic equivalents, P = .01 and .08 between groups, respectively). EX participants demonstrated a significant reduction in C-reactive protein and tended to reduce waist circumference and waist-to-hip ratio (P = .06 and .07, respectively). CONCLUSIONS: Preliminary analyses suggest that exercise training is well tolerated and sustainable in small AAA subjects over 1 year. Despite age and comorbidities, exercising AAA subjects achieve meaningful exercise targets and significantly modify activity-dependent variables.
RCT Entities:
OBJECTIVE: No effective medical therapy exists for early abdominal aortic aneurysm (AAA) disease. Lower extremity exercise improves aortic hemodynamics and reduces inflammation, but the safety and efficacy of exercise training in AAA disease is unknown. As an interim analysis of our prospective, randomized, longitudinal trial of exercise for AAA suppression, we investigated whether subjects with early disease could safely achieve target metabolic and hemodynamic goals. METHODS: One hundred eight participants were randomized to exercise training (EX) or usual care (UC). EX subjects participated in a combination of in-house and home exercise training, with efforts directed toward moderate daily exercise participation. Comparisons were made between EX and UC subjects who completed 1 year of follow-up (n = 26 and 31, respectively, mean age 72 ± 8 years). EX and UC groups were compared for safety, cardiopulmonary exercise test responses, weekly energy expenditure, and biometric indices. RESULTS: No paradoxical increase in AAA growth rate or adverse clinical events occurred as a consequence of exercise training. EX participants expended an average of 2269 ± 1207 kcal/wk and increased exercise capacity (42% increase in treadmill time, 24% increase in estimated metabolic equivalents, P = .01 and .08 between groups, respectively). EX participants demonstrated a significant reduction in C-reactive protein and tended to reduce waist circumference and waist-to-hip ratio (P = .06 and .07, respectively). CONCLUSIONS: Preliminary analyses suggest that exercise training is well tolerated and sustainable in small AAA subjects over 1 year. Despite age and comorbidities, exercising AAA subjects achieve meaningful exercise targets and significantly modify activity-dependent variables.
Authors: Ga-Young Suh; Andrea S Les; Adam S Tenforde; Shawn C Shadden; Ryan L Spilker; Janice J Yeung; Christopher P Cheng; Robert J Herfkens; Ronald L Dalman; Charles A Taylor Journal: Ann Biomed Eng Date: 2011-04-21 Impact factor: 3.934
Authors: Vittorio E Bianchi; William G Herbert; Jonathan Myers; Paul M Ribisl; Larry E Miller; Ronald L Dalman Journal: Sleep Breath Date: 2014-09-10 Impact factor: 2.816
Authors: Oliver Cronin; Barbara Bradshaw; Vikram Iyer; Margaret Cunningham; Petra Buttner; Philip J Walker; Jonathan Golledge Journal: PLoS One Date: 2013-12-27 Impact factor: 3.240
Authors: Garry A Tew; Matthew Weston; Elke Kothmann; Alan M Batterham; Joanne Gray; Karen Kerr; Denis Martin; Shah Nawaz; David Yates; Gerard Danjoux Journal: BMJ Open Date: 2014-01-10 Impact factor: 2.692
Authors: Andrew Pritchard; Paul Burns; Joao Correia; Patrick Jamieson; Peter Moxon; Joanna Purvis; Maximillian Thomas; Hannah Tighe; Karl Peter Sylvester Journal: BMJ Open Respir Res Date: 2021-11
Authors: Ricardo de Ávila Oliveira; Eliza Nakajima; Vladimir Tonello de Vasconcelos; Rachel Riera; José Carlos Costa Baptista-Silva Journal: J Vasc Bras Date: 2020-05-08